Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

Published on 4 April 2025

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) — Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants.

Explore posts connected to this topic

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and...

Interviews

February 11, 2026

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

First clinical data from Phase 1 dose-escalation study in patients

Press Releases

February 4, 2026

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

Videos

November 14, 2025

In a clinical first, Tr1X Bio showed immune reconstitution and

Interviews

February 11, 2026